Cel Sci Corporation (CVM)

[Foxwoods Man]

CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy
Method for pre-sensitizing cancer cells, making them more susceptible to follow-on treatments

CEL-SCI Corporation (NYSE MKT: CVM) announces that it has been granted a new European patent covering its investigational Phase 3 cancer immunotherapy drug Multikine* (Leucocyte Interleukin). The patent, EU Patent: EP 1 773 368 B1, titled “A Method Of Pre-Sensitizing Cancer Prior To Treatment With Radiation and/or Chemotherapy And A Novel Cytokine Mixture,” is not limited to any one particular type of cancer and can include multiple types of cancer.

This invention relates to a novel method for pre-sensitizing cancer cells prior to a therapeutic treatment such as chemotherapy or radiation therapy. This effect is created by CEL-SCI’s immunotherapy drug Multikine which, as part of its mode of action, induces cancerous cells to enter a proliferative cell cycle phase therapy, thereby potentially increasing their vulnerability to chemotherapy and radiation therapy.

Geert Kersten, Chief Executive Officer of CEL-SCI, said, “This European patent should protect one of the largest applications for Multikine, namely its use in combination with radiation and chemotherapy. Our ongoing Phase 3 clinical trial in head and neck cancer patients is administering Multikine therapy as part of a first-line treatment, before any other treatments and prior to surgery, followed by radiation or concurrent chemoradiotherapy.